Merck KGaA and Jiangsu Hengrui Ink Strategic Collaboration Deal for Next-Gen PARP1 Inhibitor
Germany-based Merck KGaA (NYSE: MRK) has announced the signing of a strategic collaboration deal with...
NYSE: MRK
Merck Reports 9% Global Sales Growth in Q3 2023, Boosted by Keytruda and Gardasil
US-based pharmaceutical giant Merck, Sharp & Dohme (MSD, NYSE: MRK) has reported a robust 9%...
MSD Halts Phase II Trials for Glutamate Modulator MK-1942 in Alzheimer’s and Depression
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced the discontinuation of two Phase II...
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...
MSD Partners with Phanes Therapeutics for Innovative Cancer Combo Therapy
Global pharmaceutical leader Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic partnership...
MSD’s Keytruda Achieves Primary Endpoint in Late-Stage NSCLC Trial
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that a late-stage trial for its...
MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...
Merck Forges Partnerships with BenevolentAI and Exscientia for Precision Drug Discovery
German pharmaceutical company Merck (NYSE: MRK) has announced two separate strategic collaborations with UK-based artificial...
FDA Grants Priority Review to MSD’s Welireg for Advanced RCC Indication Extension
The US Food and Drug Administration (FDA) has granted priority review status to an indication...
EMA’s CHMP Recommends Approval of Keytruda as Adjuvant NSCLC Treatment
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
MSD’s Sotatercept Demonstrates Positive Interim Results in Phase III PAH Studies
Merck, Sharp & Dohme (MSD; NYSE: MRK) has presented interim data from Phase III and...
Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial
Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...
Merck & Co. Becomes First Multinational to Register Unit in Hainan’s Lecheng Pilot Zone
US pharmaceutical major Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK) has officially registered a...
Sichuan Kelun Pharmaceutical Submits Biosimilar Cetuximab for NMPA Approval
Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422), through its innovative drug development subsidiary Sichuan Kelun-Biotech...
European Commission Approves Pediatric Indication for MSD’s Ervebo Ebola Vaccine
The European Commission (EC) has granted Merck, Sharp & Dohme (MSD; NYSE: MRK) approval for...
Merck’s Keytruda Approved in China for MSI-H/dMMR Advanced Solid Tumors: A Biomarker-Driven Milestone
US pharmaceutical major Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that its programmed...
MSD Plans to Introduce Over 50 New Drugs and Vaccines to China in the Next Five Years
Merck, Sharp & Dohme Inc., (MSD, NYSE: MRK), through its China R&D president Li Zhengqing,...
MSD’s Gardasil 9 HPV Vaccine Demonstrates 10-Year Efficacy in Adolescents
Merck, Sharp & Dohme (MSD; NYSE: MRK) has released long-term effectiveness data for its recombinant...
MSD’s Keytruda Gains EC Approval for First-Line HER2-Positive Gastric Cancer Treatment
The European Commission (EC) has granted an additional indication to Merck, Sharp & Dohme (MSD;...
BMS’ Reblozyl Expands Indication to Include First-Line MDS-Related Anemia Treatment
Bristol-Myers Squibb (BMS; NYSE: BMY) has received an indication extension approval from the US Food...